|
Gene: SCGB1D4 |
Gene summary for SCGB1D4 |
Gene summary. |
Gene information | Species | Human | Gene symbol | SCGB1D4 | Gene ID | 404552 |
Gene name | secretoglobin family 1D member 4 | |
Gene Alias | IIS | |
Cytomap | 11q12.3 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q6XE38 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
404552 | SCGB1D4 | AEH-subject5 | Human | Endometrium | AEH | 2.04e-19 | 8.05e-01 | -0.2953 |
404552 | SCGB1D4 | EEC-subject4 | Human | Endometrium | EEC | 4.25e-104 | 1.97e+00 | -0.2571 |
404552 | SCGB1D4 | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 3.29e-02 | -1.10e-01 | -0.1269 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Endometrium | AEH: Atypical endometrial hyperplasia | |
EEC: Endometrioid Cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | CRC | |
Stomach | GC | |
Stomach | CAG with IM | |
Stomach | CSG | |
Stomach | CAG |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SCGB1D4 | SNV | Missense_Mutation | novel | c.56C>A | p.Ala19Asp | p.A19D | Q6XE38 | protein_coding | deleterious(0) | probably_damaging(0.942) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
SCGB1D4 | insertion | In_Frame_Ins | novel | c.57_58insAAGAAA | p.Ala19_His20insLysLys | p.A19_H20insKK | Q6XE38 | protein_coding | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD | ||
SCGB1D4 | SNV | Missense_Mutation | c.90N>T | p.Glu30Asp | p.E30D | Q6XE38 | protein_coding | tolerated(0.56) | benign(0.026) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
SCGB1D4 | SNV | Missense_Mutation | c.54G>T | p.Gln18His | p.Q18H | Q6XE38 | protein_coding | tolerated(0.06) | possibly_damaging(0.735) | TCGA-EI-6507-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
SCGB1D4 | SNV | Missense_Mutation | novel | c.209C>A | p.Ser70Tyr | p.S70Y | Q6XE38 | protein_coding | deleterious(0) | probably_damaging(0.959) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
SCGB1D4 | SNV | Missense_Mutation | rs778619087 | c.221N>A | p.Arg74Gln | p.R74Q | Q6XE38 | protein_coding | deleterious(0.02) | probably_damaging(0.993) | TCGA-A5-A0VP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SCGB1D4 | SNV | Missense_Mutation | rs149931773 | c.199G>A | p.Asp67Asn | p.D67N | Q6XE38 | protein_coding | tolerated(0.17) | possibly_damaging(0.638) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
SCGB1D4 | SNV | Missense_Mutation | novel | c.209N>A | p.Ser70Tyr | p.S70Y | Q6XE38 | protein_coding | deleterious(0) | probably_damaging(0.959) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SCGB1D4 | SNV | Missense_Mutation | rs376095728 | c.122C>T | p.Ala41Val | p.A41V | Q6XE38 | protein_coding | tolerated(1) | benign(0.001) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SCGB1D4 | SNV | Missense_Mutation | c.139G>A | p.Ala47Thr | p.A47T | Q6XE38 | protein_coding | tolerated(0.19) | possibly_damaging(0.754) | TCGA-50-7109-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |